- Home
- CYCU vs EVAX Comparison
CYCU vs EVAX Comparison
Compare CYCU & EVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CYCU
- EVAX
- Stock Information
- Founded
- CYCU 2017
- EVAX 2008
- Country
- CYCU United States
- EVAX Denmark
- Employees
- CYCU N/A
- EVAX N/A
- Industry
- CYCU
- EVAX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CYCU
- EVAX Health Care
- Exchange
- CYCU Nasdaq
- EVAX Nasdaq
- Market Cap
- CYCU 17.8M
- EVAX 17.8M
- IPO Year
- CYCU N/A
- EVAX 2021
- Fundamental
- Price
- CYCU $2.65
- EVAX $5.68
- Analyst Decision
- CYCU
- EVAX Strong Buy
- Analyst Count
- CYCU 0
- EVAX 3
- Target Price
- CYCU N/A
- EVAX $12.33
- AVG Volume (30 Days)
- CYCU 650.6K
- EVAX 648.1K
- Earning Date
- CYCU 11-13-2025
- EVAX 11-06-2025
- Dividend Yield
- CYCU N/A
- EVAX N/A
- EPS Growth
- CYCU N/A
- EVAX N/A
- EPS
- CYCU N/A
- EVAX N/A
- Revenue
- CYCU $16,285,283.00
- EVAX $3,176,000.00
- Revenue This Year
- CYCU N/A
- EVAX $129.34
- Revenue Next Year
- CYCU N/A
- EVAX N/A
- P/E Ratio
- CYCU N/A
- EVAX N/A
- Revenue Growth
- CYCU N/A
- EVAX 1042.45
- 52 Week Low
- CYCU $2.79
- EVAX $1.20
- 52 Week High
- CYCU $329.70
- EVAX $13.80
- Technical
- Relative Strength Index (RSI)
- CYCU 63.06
- EVAX 49.15
- Support Level
- CYCU $3.30
- EVAX $5.51
- Resistance Level
- CYCU $5.05
- EVAX $6.01
- Average True Range (ATR)
- CYCU 0.38
- EVAX 0.88
- MACD
- CYCU 0.15
- EVAX -0.24
- Stochastic Oscillator
- CYCU 50.95
- EVAX 9.29
About CYCU Cycurion Inc. Common Stock
Cycurion Inc. provides information technology security solutions through its subsidiaries. The Company continually strives to deliver top-notch services in risk management, cybersecurity, information assurance, systems engineering, and help desk solutions. The company generates the majority of its revenue from Advisory Consulting services, with small portion revenue generated from Managed Security Service Practice (MSSP) and Software as a Service (Saas).
About EVAX Evaxion Biotech
Evaxion AS is a techBio company based on its AI platform, AI-Immunology. Evaxion's proprietary and scalable AI prediction models harness the power of artificial intelligence to decode the human immune system and develop novel immunotherapies for cancer, bacterial diseases, and viral infections. Evaxion has developed a clinical-stage oncology pipeline of novel personalised vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. The group is committed to transforming patients' lives by providing innovative and targeted treatment options.